HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
1.980
-0.060 (-2.94%)
At close: Dec 5, 2025, 4:00 PM EST
1.890
-0.090 (-4.55%)
After-hours: Dec 5, 2025, 7:56 PM EST
HCW Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 0.42 | 2.57 | 2.84 | 6.72 | - | 4.1 | Upgrade
|
| Revenue Growth (YoY) | -87.93% | -9.68% | -57.73% | - | - | - | Upgrade
|
| Cost of Revenue | 0.34 | 1.61 | 2.28 | 4.14 | - | - | Upgrade
|
| Gross Profit | 0.08 | 0.96 | 0.56 | 2.59 | - | 4.1 | Upgrade
|
| Selling, General & Admin | 6.9 | 22.85 | 13.44 | 8.41 | 5.3 | 2.75 | Upgrade
|
| Research & Development | 5.05 | 6.29 | 7.59 | 9.25 | 8.07 | 7.17 | Upgrade
|
| Operating Expenses | 13.26 | 30.44 | 26.28 | 17.67 | 13.37 | 9.92 | Upgrade
|
| Operating Income | -13.17 | -29.48 | -25.72 | -15.08 | -13.37 | -5.82 | Upgrade
|
| Interest Expense | -0.87 | -0.63 | -0.28 | -0.13 | - | - | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.09 | 0.09 | 0.76 | 0.49 | -0.06 | - | Upgrade
|
| EBT Excluding Unusual Items | -14.13 | -30.02 | -25.24 | -14.71 | -13.43 | -5.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.78 | - | 0.25 | -0.19 | - | - | Upgrade
|
| Other Unusual Items | 1.3 | - | - | - | 0.57 | - | Upgrade
|
| Pretax Income | -12.05 | -30.02 | -24.99 | -14.9 | -12.86 | -5.8 | Upgrade
|
| Net Income | -12.05 | -30.02 | -24.99 | -14.9 | -12.86 | -5.8 | Upgrade
|
| Preferred Dividends & Other Adjustments | 10.15 | - | - | - | - | 1.27 | Upgrade
|
| Net Income to Common | -22.21 | -30.02 | -24.99 | -14.9 | -12.86 | -7.07 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 62.33% | 7.97% | 0.30% | 90.84% | 296.07% | 10.56% | Upgrade
|
| EPS (Basic) | -14.70 | -30.96 | -27.83 | -16.64 | -27.41 | -59.70 | Upgrade
|
| EPS (Diluted) | -14.70 | -30.96 | -27.83 | -16.64 | -27.41 | -59.70 | Upgrade
|
| Free Cash Flow | -12.98 | -14.49 | -28.72 | -20.66 | -11.02 | -10.62 | Upgrade
|
| Free Cash Flow Per Share | -8.60 | -14.94 | -31.97 | -23.07 | -23.49 | -89.62 | Upgrade
|
| Gross Margin | 20.00% | 37.38% | 19.72% | 38.48% | - | 100.00% | Upgrade
|
| Operating Margin | -3120.97% | -1148.50% | -904.96% | -224.32% | - | -142.07% | Upgrade
|
| Profit Margin | -5261.76% | -1169.70% | -879.52% | -221.67% | - | -172.54% | Upgrade
|
| Free Cash Flow Margin | -3076.68% | -564.48% | -1010.51% | -307.36% | - | -258.99% | Upgrade
|
| EBITDA | -11.6 | -28.3 | -24.58 | -14.49 | -12.82 | -5.25 | Upgrade
|
| EBITDA Margin | - | - | - | -215.55% | - | -128.10% | Upgrade
|
| D&A For EBITDA | 1.57 | 1.18 | 1.14 | 0.59 | 0.54 | 0.57 | Upgrade
|
| EBIT | -13.17 | -29.48 | -25.72 | -15.08 | -13.37 | -5.82 | Upgrade
|
| EBIT Margin | - | - | - | -224.32% | - | -142.07% | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 4.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.